-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: Determine the Beijing new drug industry's hydrochloric acid koala viron tablets and the original research has been listed equivalent.
today, Kyodo Pharmaceuticals announced that its application for a simplified new drug (ANDA) for hydrochloric acid tablets declared to the FDA has been approved.
has determined that the company's application for a listing of the caeringuric acid Koala (625mg) and the original research Daiichi Sankyo (First Third Pharmaceuticals) has been listed as the acetate of colloquial tablets (commodity name: Welchol) equivalent.
hydrochloric acid koala is a new type of bile acid chelating agent developed by Daiichi Sankyo as an auxiliary treatment for diet and exercise for adult patients with primary hyperlipidemia, and can improve blood sugar control in adults with type II diabetes.
the main producers of hydrochloric acid koalas currently in the U.S. market are Daiichi Sankyo, Impax Labs Inc,Glenmark Pharms Ltd., Dr Reddys, etc.
Sales in the U.S. market for Coravellon tablets in 2019 were $210 million, according to IMS data.
.